Thermo Fisher Scientific Inc. $TMO Shares Sold by Congress Asset Management Co.

Key Points

• Congress Asset Management cut its Thermo Fisher stake by 46.8% in the third quarter, selling 3,970 shares and retaining 4,505 shares valued at approximately $3.04 million. Institutional investors still own 89.23% of the company.
• Analyst sentiment remains broadly positive, with Thermo Fisher carrying a “Moderate Buy” consensus rating and an average price target of $635.55, although some firms recently downgraded the stock to “underperform” or “underweight.”
• Thermo Fisher reported quarterly EPS of $6.03 and revenue of $11.99 billion, exceeding estimates, while revenue grew 10.5% year over year. Shares opened at $660.97, near the upper end of their 52-week range, amid continued insider selling and valuation concerns.

Congress Asset Management Co. lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 46.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,505 shares of the medical research company's stock after selling 3,970 shares during the quarter. Congress Asset Management Co.'s holdings in Thermo Fisher Scientific were worth $3,041,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Legacy Wealth Managment LLC ID raised its position in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after acquiring an additional 22 shares during the last quarter. Kilter Group LLC acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth $25,000. Allied Private Wealth LLC acquired a new position in Thermo Fisher Scientific in the second quarter valued at about $26,000. MBM Wealth Consultants LLC bought a new position in Thermo Fisher Scientific during the first quarter worth about $29,000. Finally, Pingora Partners LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $30,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TMO has been the topic of a number of analyst reports. CLSA started coverage on shares of Thermo Fisher Scientific in a research report on Thursday, September 3rd. They issued an "outperform" rating and a C$748.00 price target on the stock. Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, October 3rd. Citigroup cut shares of Thermo Fisher Scientific from a "buy" rating to an "underperform" rating in a research report on Wednesday, September 9th. Finally, Wells Fargo & Company lowered Thermo Fisher Scientific from an "overweight" rating to an "underweight" rating in a report on Wednesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $635.55.

Thermo Fisher Scientific Stock Performance

TMO opened at $660.97 on Thursday. The company has a market capitalization of $244.39 billion, a price-to-earnings ratio of 35.56, a P/E/G ratio of 2.75 and a beta of 0.87. The business's 50-day moving average price is $624.23 and its two-hundred day moving average price is $539.29. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $694.33. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period last year, the company earned $4.28 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Michael Shafer sold 25,500 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the firm's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president owned 14,784 shares of the company's stock, valued at $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 73,768 shares of company stock valued at $44,122,820 in the last ninety days. 0.33% of the stock is currently owned by insiders.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: New clinical-trial agreement supports PPD growth. Thermo Fisher’s PPD clinical research business signed an agreement with Quantum BioPharma to launch a Phase 2, randomized trial of its Lucid-MS multiple-sclerosis therapy. The deal should provide additional clinical-research revenue and reinforces PPD’s role as a contract research partner for emerging biopharmaceutical companies. Quantum BioPharma Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS Trial
• Positive Sentiment: Expanded drug-development offerings could support demand. At CPHI Milan 2026, Thermo Fisher highlighted new and expanded drug-development, manufacturing and clinical capabilities, including its OSD Express solution. The initiatives are intended to help pharmaceutical and biotechnology customers accelerate commercialization and improve manufacturing predictability, supporting the company’s diversified growth strategy. Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities
• Positive Sentiment: Investment commentary remains constructive. ClearBridge Investments cited strong third-quarter guidance, broadening end-market demand and Thermo Fisher’s multi-year outlook. Separate analysis also pointed to innovation, acquisitions and exposure to multiple research markets as potential growth drivers. Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook
• Neutral Sentiment: A market report identified Thermo Fisher as a major participant in the cell-based assay and high-content screening market, where automation, 3D assays and immuno-oncology research are driving demand. The report is industry-wide rather than company-specific, so its direct effect on TMO is limited. Cell-Based Assay and High Content Screening Market Report
• Negative Sentiment: Valuation and macroeconomic risks remain potential restraints. Commentary noted currency exposure and uncertain research spending, while TMO trades at a relatively elevated valuation after reaching a new one-year high. Those factors may encourage profit-taking despite the favorable operating outlook. Is This the Right Time to Add TMO Stock to Your Portfolio?

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.